Provided By GlobeNewswire
Last update: Jun 10, 2024
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST.
Read more at globenewswire.comNASDAQ:LVTX (2/21/2025, 8:00:00 PM)
0.9575
+0.02 (+2.41%)
Find more stocks in the Stock Screener